GO Therapeutics

GO Therapeutics, Inc. is a biotechnology company based in Natick, Massachusetts, founded in 2014. The company specializes in oncology, focusing on identifying tumor-specific targets in the cancer glycoproteome. GO Therapeutics develops high-affinity antibodies aimed at advanced solid tumor therapies, addressing challenges in current treatment modalities.

The company has a diverse pipeline of preclinical-stage candidates targeting solid tumors and specific indications such as liver cancer. Its lead product is GO-2, with additional programs including GO-R800, GO-M400, and GO-14C9. GO Therapeutics primarily works with antibodies and has developed various drug modalities, including antibody-drug conjugates and CAR-T therapies.

GO Therapeutics also offers partnering opportunities for its discovery platform, collaborating on the development of innovative cancer treatments. A notable partnership includes a licensing agreement with Roche for a bispecific cancer treatment, valued at up to $195 million.